New eye scan could spot iris tumors better

NCT ID NCT03809585

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study uses a special eye scan called OCT angiography to look at iris tumors in 100 people. Researchers want to see if this scan can tell the difference between harmless and cancerous growths better than current methods. Participants include people with iris tumors and healthy volunteers for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could improve how doctors diagnose iris tumors, potentially reducing the need for invasive procedures.

What could go wrong

This is an observational study, not a treatment trial. It may not lead to immediate changes in patient care, and results depend on accurate imaging comparisons.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IRIS TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

iris neoplasm melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••